NuVasive To Expand Global Presence, Product Portfolio With Ellipse Buy
This article was originally published in The Gray Sheet
Executive Summary
NuVasive says Ellipse's magnetically adjustable implant systems will open new global markets, particularly in the pediatric space, and complement its current portfolio. Analysts say the move is positive, but at least one observer believes that NuVasive might have paid too much for the deal.
You may also be interested in...
NuVasive Settles With DOJ On Medicare Fraud Charges
The spine device firm announced a definitive settlement with the Department of Justice, with a fine of $13.5 million, plus fees and accrued interest
Next Steps For NuVasive Following CEO Resignation
The resignation of CEO Alex Lukianov could signal a shift in the spine firm's approach to sales and profitability that could ultimately make NuVasive as a more attractive acquisition candidate.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.